108 related articles for article (PubMed ID: 16608732)
1. Enhanced liver targeting of 5-fluorouracil using galactosylated human serum albumin as a carrier molecule.
Cai C; Zhou K; Wu Y; Wu L
J Drug Target; 2006 Feb; 14(2):55-61. PubMed ID: 16608732
[TBL] [Abstract][Full Text] [Related]
2. Galactosylated nanostructured lipid carriers for delivery of 5-FU to hepatocellular carcinoma.
Varshosaz J; Hassanzadeh F; Sadeghi H; Khadem M
J Liposome Res; 2012 Sep; 22(3):224-36. PubMed ID: 22385296
[TBL] [Abstract][Full Text] [Related]
3. Lectin-mediated cytotoxicity and specificity of 5-fluorouracil conjugated with peanut agglutinin (5-Fu-PNA) in vitro.
Cai Q; Zhang ZR
J Drug Target; 2005 May; 13(4):251-7. PubMed ID: 16051537
[TBL] [Abstract][Full Text] [Related]
4. Multidrug Delivery Systems Based on Human Serum Albumin for Combination Therapy with Three Anticancer Agents.
Qi J; Zhang Y; Gou Y; Lee P; Wang J; Chen S; Zhou Z; Wu X; Yang F; Liang H
Mol Pharm; 2016 Sep; 13(9):3098-105. PubMed ID: 27453125
[TBL] [Abstract][Full Text] [Related]
5. Organ distribution of 5-fluorouracil loaded gelatine microspheres in mice.
Hao X; Cheng G; Zou M; Sun J; Cui F
Pharmazie; 2004 Sep; 59(9):709-12. PubMed ID: 15497754
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics and tissue distribution of 5-fluorouracil encapsulated by galactosylceramide liposomes in mice.
Jin Y; Li J; Rong LF; Lü XW; Huang Y; Xu SY
Acta Pharmacol Sin; 2005 Feb; 26(2):250-6. PubMed ID: 15663907
[TBL] [Abstract][Full Text] [Related]
7. Enhanced hepatocyte uptake and liver targeting of methotrexate using galactosylated albumin as a carrier.
Han JH; Oh YK; Kim DS; Kim CK
Int J Pharm; 1999 Oct; 188(1):39-47. PubMed ID: 10528081
[TBL] [Abstract][Full Text] [Related]
8. Microprocessor-controlled iontophoretic drug delivery of 5-fluorouracil: pharmacodynamic and pharmacokinetic study.
Chandrashekar NS; Shobha Rani RH
J BUON; 2007; 12(4):529-34. PubMed ID: 18067212
[TBL] [Abstract][Full Text] [Related]
9. Synthesis of Biotin-Modified Galactosylated Chitosan Nanoparticles and Their Characteristics in Vitro and in Vivo.
Cheng M; Ma D; Zhi K; Liu B; Zhu W
Cell Physiol Biochem; 2018; 50(2):569-584. PubMed ID: 30308481
[TBL] [Abstract][Full Text] [Related]
10. Preparation and characterization of a biodegradable drug targeting system for anticancer drug delivery: microsphere-antibody conjugate.
Muvaffak A; Gurhan I; Gunduz U; Hasirci N
J Drug Target; 2005 Apr; 13(3):151-9. PubMed ID: 16036303
[TBL] [Abstract][Full Text] [Related]
11. Translocator protein ligand-PLGA conjugated nanoparticles for 5-fluorouracil delivery to glioma cancer cells.
Laquintana V; Denora N; Lopalco A; Lopedota A; Cutrignelli A; Lasorsa FM; Agostino G; Franco M
Mol Pharm; 2014 Mar; 11(3):859-71. PubMed ID: 24410438
[TBL] [Abstract][Full Text] [Related]
12. Recent Advances in Designing 5-Fluorouracil Delivery Systems: A Stepping Stone in the Safe Treatment of Colorectal Cancer.
Entezar-Almahdi E; Mohammadi-Samani S; Tayebi L; Farjadian F
Int J Nanomedicine; 2020; 15():5445-5458. PubMed ID: 32801699
[TBL] [Abstract][Full Text] [Related]
13. Stealth liposomal 5-fluorouracil with or without degradable starch microspheres for hepatic arterial infusion in the treatment of liver metastases. An animal study in VX-2 liver tumor-bearing rabbits.
Pohlen U; Reszka R; Schneider P; Buhr HJ; Berger G
Anticancer Res; 2004; 24(3a):1699-704. PubMed ID: 15274343
[TBL] [Abstract][Full Text] [Related]
14. Fractional laser-assisted topical delivery leads to enhanced, accelerated and deeper cutaneous 5-fluorouracil uptake.
Wenande E; Olesen UH; Nielsen MM; Janfelt C; Hansen SH; Anderson RR; Haedersdal M
Expert Opin Drug Deliv; 2017 Mar; 14(3):307-317. PubMed ID: 27835937
[TBL] [Abstract][Full Text] [Related]
15. Ethogel topical formulation for increasing the local bioavailability of 5-fluorouracil: a mechanistic study.
Puri R; Jain S
Anticancer Drugs; 2012 Oct; 23(9):923-34. PubMed ID: 22926258
[TBL] [Abstract][Full Text] [Related]
16. In vivo biodistribution for tumor targeting of 5-fluorouracil (5-FU) loaded N-succinyl-chitosan (Suc-Chi) nanoparticles.
Yan C; Gu J; Guo Y; Chen D
Yakugaku Zasshi; 2010 Jun; 130(6):801-4. PubMed ID: 20519858
[TBL] [Abstract][Full Text] [Related]
17. [Pharmacokinetics and distribution of 5-Fu magnetic albumin deuto-microsphere in normal and tumor-bearing mice].
Xu R; Shi SJ; Zhou SC; Zheng JW; Chen H; Zou SQ; Zeng FD
Yao Xue Xue Bao; 2007 Jan; 42(1):66-70. PubMed ID: 17520810
[TBL] [Abstract][Full Text] [Related]
18. Intra-aortal therapy with 5-fluorouracil- polyethylene glycol stealth liposomes: does the metabolism of 5-fluorouracil into 5-fluoro-2'-deoxyuridine depend on ph value?. An animal study in VX-2 liver tumor-bearing rabbits.
Pohlen U; Binnenhei M; Reszka R; Buhr HJ; Berger G
Chemotherapy; 2004 Jun; 50(2):67-75. PubMed ID: 15211080
[TBL] [Abstract][Full Text] [Related]
19. Drug retention and distribution after intratumoral chemotherapy with fluorouracil/epinephrine injectable gel in human pancreatic cancer xenografts.
Smith JP; Kanekal S; Patawaran MB; Chen JY; Jones RE; Orenberg EK; Yu NY
Cancer Chemother Pharmacol; 1999; 44(4):267-74. PubMed ID: 10447573
[TBL] [Abstract][Full Text] [Related]
20. Formulation and pharmacokinetics of thermosensitive stealth® liposomes encapsulating 5-Fluorouracil.
Al Sabbagh C; Tsapis N; Novell A; Calleja-Gonzalez P; Escoffre JM; Bouakaz A; Chacun H; Denis S; Vergnaud J; Gueutin C; Fattal E
Pharm Res; 2015 May; 32(5):1585-603. PubMed ID: 25416027
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
